Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro

Mir A. Hoda, Christine Pirker, Yawen Dong, Karin Schelch, Petra Heffeter, Kushtrim Kryeziu, Sushilla van Schoonhoven, Thomas Klikovits, Viktoria Laszlo, Anita Rozsas, Judit Ozsvar, Walter Klepetko, Balazs Döme, Michael Grusch, Balazs Hegedüs, Walter Berger

Mol Cancer Ther (2016) 15 (10): 2357–2369.

DOI: https://doi.org/10.1158/1535-7163.MCT-15-0846

Published: 02 October 2016

View article

Includes: Multimedia, Supplementary data

Journal Articles

Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts

Verena Paulitschke, Walter Berger, Philipp Paulitschke, Elisabeth Hofstätter, Bernhard Knapp, Ruth Dingelmaier-Hovorka, Dagmar Födinger, Walter Jäger, Thomas Szekeres, Anastasia Meshcheryakova, Andrea Bileck, Christine Pirker, Hubert Pehamberger, Christopher Gerner, Rainer Kunstfeld

Mol Cancer Ther (2015) 14 (3): 757–768.

DOI: https://doi.org/10.1158/1535-7163.MCT-14-0701

Published: 09 March 2015

View article

Includes: Supplementary data

Journal Articles

A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression

Franziska van Zijl, Sabine Mall, Georg Machat, Christine Pirker, Robert Zeillinger, Andreas Weinhaeusel, Martin Bilban, Walter Berger, Wolfgang Mikulits

Mol Cancer Ther (2011) 10 (5): 850–860.

DOI: https://doi.org/10.1158/1535-7163.MCT-10-0917

Published: 08 May 2011

View article

Includes: Supplementary data

Journal Articles

Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells

Beata Herberger, Walter Berger, Harald Puhalla, Katharina Schmid, Sabine Novak, Anita Brandstetter, Christine Pirker, Thomas Gruenberger, Martin Filipits

Mol Cancer Ther (2009) 8 (6): 1547–1556.

DOI: https://doi.org/10.1158/1535-7163.MCT-09-0003

Published: 10 June 2009

View article

Includes: Supplementary data

Journal Articles

Na⁺/K⁺-ATPase as a potential target to combat melanoma

Veronique Mathieu, Christine Pirker, Mathieu Vernier, Tatjana Mijatovic, Walter Berger, Robert Kiss

Mol Cancer Ther (2007) 6 (11_Supplement): B202.

Published: 01 November 2007

View article

NARROW

Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro

Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts

A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression

Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells

Na⁺/K⁺-ATPase as a potential target to combat melanoma

Email alerts

AACR Journals

Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro

Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts

A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression

Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells

Na+/K+-ATPase as a potential target to combat melanoma

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Na⁺/K⁺-ATPase as a potential target to combat melanoma